US6440457B1
(en)
*
|
1993-05-27 |
2002-08-27 |
Alza Corporation |
Method of administering antidepressant dosage form
|
FI102944B
(fi)
*
|
1996-06-19 |
1999-03-31 |
Nokia Mobile Phones Ltd |
Potilaan hoitolaite sekä hoitojärjestelmä
|
ES2362418T3
(es)
|
1997-12-08 |
2011-07-05 |
Nycomed Gmbh |
Nueva forma de supositorio que comprende un compuesto activo ácido-lábil.
|
KR20010042547A
(ko)
*
|
1998-04-09 |
2001-05-25 |
유란드 인터내셔날 에스.피.아. |
소수성 폴리머로 코팅된 코어를 갖는 습윤성 마이크로캡슐
|
US20060159756A1
(en)
*
|
1999-09-10 |
2006-07-20 |
Brita Sjoblom |
Method to obtain microparticles containing an H+,K+-ATP-ASE inhibitor
|
US20060153914A1
(en)
*
|
1999-12-10 |
2006-07-13 |
Biovail Laboratories International S.R.L. |
Chronotherapeutic diltiazem formulations and the administration thereof
|
AU2001234005B2
(en)
*
|
2000-02-28 |
2006-01-19 |
Pharmakodex Limited |
Improvements in or relating to the delivery of oral drugs
|
WO2002000216A1
(en)
*
|
2000-06-28 |
2002-01-03 |
Teva Pharmaceutical Industries Ltd. |
Carvedilol
|
FR2811571B1
(fr)
*
|
2000-07-11 |
2002-10-11 |
Flamel Tech Sa |
Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif
|
US6482440B2
(en)
|
2000-09-21 |
2002-11-19 |
Phase 2 Discovery, Inc. |
Long acting antidepressant microparticles
|
GB0026512D0
(en)
*
|
2000-10-30 |
2000-12-13 |
Benfell S Ltd |
Protective beacon
|
FR2816840B1
(fr)
*
|
2000-11-17 |
2004-04-09 |
Flamel Tech Sa |
Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
|
SE0100200D0
(sv)
|
2001-01-24 |
2001-01-24 |
Astrazeneca Ab |
New film coating
|
US20050192220A1
(en)
*
|
2001-02-05 |
2005-09-01 |
Gevys Pharmaceuticas Ltd. |
Composition and method for potentiating drugs
|
US6833377B2
(en)
|
2001-02-05 |
2004-12-21 |
Gevys Pharmaceuticals Ltd. |
Composition and method for potentiating drugs
|
SE0100822D0
(sv)
*
|
2001-03-09 |
2001-03-09 |
Astrazeneca Ab |
Method II to obtain microparticles
|
SE0100824D0
(sv)
*
|
2001-03-09 |
2001-03-09 |
Astrazeneca Ab |
Method III to obtain microparticles
|
FR2825023B1
(fr)
|
2001-05-23 |
2005-04-15 |
Flamel Tech Sa |
Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
|
JP5080716B2
(ja)
*
|
2001-07-20 |
2012-11-21 |
サイコジェニックス・インコーポレーテッド |
注意欠陥・多動性障害の治療
|
US8101209B2
(en)
|
2001-10-09 |
2012-01-24 |
Flamel Technologies |
Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
|
FR2830447B1
(fr)
*
|
2001-10-09 |
2004-04-16 |
Flamel Tech Sa |
Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
|
US6710184B2
(en)
|
2002-01-15 |
2004-03-23 |
Teva Pharmaceutical Industries Ltd. |
Crystalline solids of carvedilol and processes for their preparation
|
FR2837100B1
(fr)
*
|
2002-03-18 |
2004-07-23 |
Flamel Tech Sa |
Comprimes a bases de microcapsules a liberation modifiee
|
WO2003084517A2
(fr)
*
|
2002-04-09 |
2003-10-16 |
Flamel Technologies |
Suspension orale de microcapsules d’amoxicilline
|
FR2843881B1
(fr)
*
|
2002-09-02 |
2006-06-02 |
Flamel Tech Sa |
Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
|
PT1492511E
(pt)
*
|
2002-04-09 |
2009-04-09 |
Flamel Tech Sa |
Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s)
|
FR2843880B1
(fr)
*
|
2002-09-02 |
2006-06-02 |
Flamel Tech Sa |
Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee d'amoxicilline
|
US7008979B2
(en)
*
|
2002-04-30 |
2006-03-07 |
Hydromer, Inc. |
Coating composition for multiple hydrophilic applications
|
US20040208936A1
(en)
*
|
2002-07-22 |
2004-10-21 |
Roland Chorin |
Novel compositions
|
FR2842736B1
(fr)
*
|
2002-07-26 |
2005-07-22 |
Flamel Tech Sa |
Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
|
FR2842735B1
(fr)
*
|
2002-07-26 |
2006-01-06 |
Flamel Tech Sa |
Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
|
JP2006521366A
(ja)
*
|
2003-03-28 |
2006-09-21 |
シグモイド・バイオテクノロジーズ・リミテッド |
シームレスマイクロカプセルを含む固形経口剤形
|
US8802139B2
(en)
*
|
2003-06-26 |
2014-08-12 |
Intellipharmaceutics Corp. |
Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
|
US7314640B2
(en)
*
|
2003-07-11 |
2008-01-01 |
Mongkol Sriwongjanya |
Formulation and process for drug loaded cores
|
MEP3608A
(en)
*
|
2003-08-08 |
2011-05-10 |
Biovail Lab Int Srl |
Modified-release tablet of bupropion hydrochloride
|
JP5072364B2
(ja)
*
|
2003-11-25 |
2012-11-14 |
スミスクライン ビーチャム (コーク) リミテッド |
カルベジロール遊離塩基、カルベジロール塩、無水形態またはその溶媒和物、対応する医薬組成物、制御放出処方および治療またはデリバリー方法
|
EP1686967A4
(en)
*
|
2003-11-25 |
2012-08-08 |
Smithkline Beecham Cork Ltd |
CARVEDILOL-FREE BASE, SALTS, WATER-FREE FORMS OR SOLVATES THEREOF, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, CONTROLLED RELEASE FORMULAS AND TREATMENT OR DISPOSAL PROCEDURES
|
EP1750717B1
(en)
*
|
2004-02-11 |
2017-07-19 |
Rubicon Research Private Limited |
Controlled release pharmaceutical compositions with improved bioavailability
|
US20070122488A1
(en)
*
|
2004-02-25 |
2007-05-31 |
Erich Windhab |
Multi-functional microcapsules and method and device for manufacturing same
|
DE102004029732A1
(de)
|
2004-06-21 |
2006-01-19 |
Basf Ag |
Hilfsmittel enthaltend Cyclohexanpolycarbonsäurederivate
|
US8394409B2
(en)
*
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
US10624858B2
(en)
*
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
CA2578224A1
(en)
*
|
2004-08-25 |
2006-03-09 |
Essentialis, Inc. |
Pharmaceutical formulations of potassium atp channel openers and uses thereof
|
US20080020018A1
(en)
*
|
2004-09-27 |
2008-01-24 |
Joey Moodley |
Combination Products
|
EP2801354B1
(en)
|
2004-10-08 |
2017-02-08 |
Forward Pharma A/S |
Controlled release pharmaceutical compositions comprising a fumaric acid ester
|
FR2878159B1
(fr)
*
|
2004-11-24 |
2008-10-17 |
Flamel Technologies Sa |
Medicament oral a liberation modifiee d'au moins un principe actif sous forme multimicrocapsulaire
|
FR2881652B1
(fr)
*
|
2005-02-08 |
2007-05-25 |
Flamel Technologies Sa |
Forme pharmaceutique orale microparticulaire anti-mesuage
|
FR2882260A1
(fr)
*
|
2005-02-21 |
2006-08-25 |
Flamel Technologies Sa |
Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
|
FR2882259A1
(fr)
*
|
2005-02-21 |
2006-08-25 |
Flamel Technologies Sa |
Forme pharmaceutique orale multimicroparticulaire a liberation modifiee de losartan
|
WO2006087394A1
(fr)
*
|
2005-02-21 |
2006-08-24 |
Flamel Technologies |
Forme pharmaceutique orale de losartan
|
FR2884145A1
(fr)
*
|
2005-04-06 |
2006-10-13 |
Flamel Technologies Sa |
Forme pharmaceutique orale de losartan
|
US9757384B2
(en)
|
2005-04-06 |
2017-09-12 |
Essentialis, Inc. |
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
|
FR2885526B1
(fr)
*
|
2005-05-13 |
2007-07-27 |
Flamel Technologies Sa |
Medicament oral a base d'inhibiteur de pompe a protons
|
ATE480229T1
(de)
*
|
2005-05-24 |
2010-09-15 |
Flamel Tech Sa |
Orale pharmazeutische zusammensetzung zur behandlung einer cox-2-vermittelten erkrankung
|
FR2886150B1
(fr)
*
|
2005-05-24 |
2007-08-24 |
Flamel Technologies Sa |
Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
|
US20070166378A1
(en)
*
|
2005-06-09 |
2007-07-19 |
Flamel Technologies, Inc. |
Oral ribavirin pharmaceutical compositions
|
WO2006135757A1
(en)
*
|
2005-06-09 |
2006-12-21 |
Teva Pharmaceutical Industries Ltd. |
Crystalline forms of carvedilol and processes for their preparation
|
WO2006131790A2
(en)
*
|
2005-06-09 |
2006-12-14 |
Flamel Technologies |
Oral ribavirin pharmaceutical composition
|
WO2006133733A1
(en)
|
2005-06-13 |
2006-12-21 |
Flamel Technologies |
Oral dosage form comprising an antimisuse system
|
FR2891459B1
(fr)
*
|
2005-09-30 |
2007-12-28 |
Flamel Technologies Sa |
Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
|
WO2007052436A1
(ja)
*
|
2005-10-31 |
2007-05-10 |
Niigata University |
マイクロカプセル及びその製造方法
|
US8652529B2
(en)
|
2005-11-10 |
2014-02-18 |
Flamel Technologies |
Anti-misuse microparticulate oral pharmaceutical form
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
AU2006335153B2
(en)
*
|
2006-01-05 |
2012-03-15 |
Essentialis, Inc. |
Salts of potassium ATP channel openers and uses thereof
|
US20070264346A1
(en)
*
|
2006-02-16 |
2007-11-15 |
Flamel Technologies |
Multimicroparticulate pharmaceutical forms for oral administration
|
US9561188B2
(en)
*
|
2006-04-03 |
2017-02-07 |
Intellipharmaceutics Corporation |
Controlled release delivery device comprising an organosol coat
|
US10960077B2
(en)
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
US20100297226A1
(en)
*
|
2006-06-01 |
2010-11-25 |
Dexcel Pharma Technologies Ltd. |
Multiple unit pharmaceutical formulation
|
US8022094B2
(en)
*
|
2006-06-28 |
2011-09-20 |
Teva Pharmaceutical Industries Ltd. |
Carvedilol phosphate
|
US20080081067A1
(en)
*
|
2006-10-03 |
2008-04-03 |
Gupta Manishkumar |
Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
|
US20080292695A1
(en)
*
|
2006-12-01 |
2008-11-27 |
Kristin Arnold |
Carvedilol forms, compositions, and methods of preparation thereof
|
US20090028935A1
(en)
*
|
2006-12-01 |
2009-01-29 |
Kristin Arnold |
Carvedilol forms, compositions, and methods of preparation thereof
|
US20080207726A1
(en)
*
|
2007-02-26 |
2008-08-28 |
Santiago Ini |
Process for the purification of carvedilol or its salts thereof
|
CA2683415C
(en)
|
2007-04-04 |
2020-12-08 |
Sigmoid Pharma Limited |
An oral pharmaceutical composition
|
EP2586428B1
(en)
|
2007-04-26 |
2023-11-08 |
Sublimity Therapeutics Limited |
Manufacture of multiple minicapsules
|
EP2063875A2
(en)
*
|
2007-05-01 |
2009-06-03 |
Sigmoid Pharma Limited |
Combination pharmaceutical compositions
|
JP2010532383A
(ja)
*
|
2007-07-02 |
2010-10-07 |
エッセンシャリス,インク. |
カリウムatpチャネル開口薬の塩およびその使用
|
NZ589469A
(en)
*
|
2008-05-20 |
2012-08-31 |
Cerenis Therapeutics Holding S A |
Niacin and NSAID combination for reducing niacin-induced flushing
|
US9901551B2
(en)
|
2009-04-20 |
2018-02-27 |
Ambra Bioscience Llc |
Chemosensory receptor ligand-based therapies
|
US8828953B2
(en)
*
|
2009-04-20 |
2014-09-09 |
NaZura BioHealth, Inc. |
Chemosensory receptor ligand-based therapies
|
CA2758976C
(en)
|
2009-04-20 |
2015-02-03 |
Alain Baron |
Chemosensory receptor ligand-based therapies
|
US9278070B2
(en)
|
2009-05-18 |
2016-03-08 |
Sigmoid Pharma Limited |
Composition comprising oil drops
|
FR2945947B1
(fr)
|
2009-05-29 |
2011-07-29 |
Flamel Tech Sa |
Compositions pharmaceutiques flottantes a liberation controlee
|
FR2945945B1
(fr)
|
2009-05-29 |
2011-07-29 |
Flamel Tech Sa |
Procede de preparation de particules creuses et leurs applications
|
GB2485327A
(en)
|
2009-08-12 |
2012-05-09 |
Sigmoid Pharma Ltd |
Immunomodulatory compositions comprising a polymer matrix and an oil phase
|
US20120076865A1
(en)
|
2010-03-24 |
2012-03-29 |
Jazz Pharmaceuticals, Inc. |
Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
|
US9486463B2
(en)
|
2010-10-19 |
2016-11-08 |
Ambra Bioscience Llc |
Chemosensory receptor ligand-based therapies
|
GB201020032D0
(en)
|
2010-11-25 |
2011-01-12 |
Sigmoid Pharma Ltd |
Composition
|
KR20140035331A
(ko)
|
2011-01-07 |
2014-03-21 |
엘셀릭스 테라퓨틱스 인코포레이티드 |
화학감각 수용체 리간드-기반 요법
|
US9795792B2
(en)
|
2011-02-25 |
2017-10-24 |
Medtronic, Inc. |
Emergency mode switching for non-pacing modes
|
US8900631B2
(en)
*
|
2011-04-28 |
2014-12-02 |
Health Science Funding, LLC |
Dosage form to increase prasterone bioavailability
|
HUE055562T2
(hu)
|
2011-11-23 |
2021-11-29 |
Therapeuticsmd Inc |
Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel
|
US9301920B2
(en)
|
2012-06-18 |
2016-04-05 |
Therapeuticsmd, Inc. |
Natural combination hormone replacement formulations and therapies
|
KR20190120430A
(ko)
|
2012-01-06 |
2019-10-23 |
엘셀릭스 테라퓨틱스 인코포레이티드 |
바이구아나이드 조성물 및 대사 장애를 치료하는 방법
|
JP6175074B2
(ja)
|
2012-01-06 |
2017-08-02 |
エルセリクス セラピューティクス インコーポレイテッド |
代謝障害を治療するための組成物および方法
|
EP2819675A4
(en)
|
2012-02-27 |
2015-07-22 |
Essentialis Inc |
SALTS OF KALIUM ATP CHANNEL OPENERS AND USES THEREOF
|
WO2013158928A2
(en)
|
2012-04-18 |
2013-10-24 |
Elcelyx Therapeutics, Inc. |
Chemosensory receptor ligand-based therapies
|
US20150196640A1
(en)
|
2012-06-18 |
2015-07-16 |
Therapeuticsmd, Inc. |
Progesterone formulations having a desirable pk profile
|
US10806697B2
(en)
|
2012-12-21 |
2020-10-20 |
Therapeuticsmd, Inc. |
Vaginal inserted estradiol pharmaceutical compositions and methods
|
US20130338122A1
(en)
|
2012-06-18 |
2013-12-19 |
Therapeuticsmd, Inc. |
Transdermal hormone replacement therapies
|
US10806740B2
(en)
|
2012-06-18 |
2020-10-20 |
Therapeuticsmd, Inc. |
Natural combination hormone replacement formulations and therapies
|
GB201212010D0
(en)
|
2012-07-05 |
2012-08-22 |
Sigmoid Pharma Ltd |
Formulations
|
JP2015522080A
(ja)
|
2012-07-11 |
2015-08-03 |
エルセリクス セラピューティクス インコーポレイテッド |
スタチン、ビグアナイド、およびさらなる薬剤を含む心血管代謝性リスクを減少させるための組成物
|
US20140141075A1
(en)
|
2012-11-21 |
2014-05-22 |
Warner Chilcott Company, Llc |
5-aminosalicylic acid capsule formulation
|
US11266661B2
(en)
|
2012-12-21 |
2022-03-08 |
Therapeuticsmd, Inc. |
Vaginal inserted estradiol pharmaceutical compositions and methods
|
US9180091B2
(en)
|
2012-12-21 |
2015-11-10 |
Therapeuticsmd, Inc. |
Soluble estradiol capsule for vaginal insertion
|
US10568891B2
(en)
|
2012-12-21 |
2020-02-25 |
Therapeuticsmd, Inc. |
Vaginal inserted estradiol pharmaceutical compositions and methods
|
US11246875B2
(en)
|
2012-12-21 |
2022-02-15 |
Therapeuticsmd, Inc. |
Vaginal inserted estradiol pharmaceutical compositions and methods
|
US10537581B2
(en)
|
2012-12-21 |
2020-01-21 |
Therapeuticsmd, Inc. |
Vaginal inserted estradiol pharmaceutical compositions and methods
|
US10471072B2
(en)
|
2012-12-21 |
2019-11-12 |
Therapeuticsmd, Inc. |
Vaginal inserted estradiol pharmaceutical compositions and methods
|
SG11201505240QA
(en)
|
2013-01-05 |
2015-08-28 |
Elcelyx Therapeutics Inc |
Delayed-release composition comprising biguanide
|
EP3300015B1
(en)
|
2013-03-12 |
2019-08-14 |
Panacea Biomatx Inc. |
System for making customized formulations for individuals
|
GB201319791D0
(en)
|
2013-11-08 |
2013-12-25 |
Sigmoid Pharma Ltd |
Formulations
|
EP3079663A1
(en)
|
2013-12-13 |
2016-10-19 |
Biogen MA Inc. |
Controlled release dosage form for once daily administration of dimethyl fumarate
|
EP3145489A1
(en)
|
2014-05-22 |
2017-03-29 |
TherapeuticsMD, Inc. |
Natural combination hormone replacement formulations and therapies
|
ES2919874T3
(es)
*
|
2014-09-24 |
2022-07-28 |
Vital Beverages Global Inc |
Composiciones y métodos para el suministro selectivo en el tubo gastrointestinal
|
KR20170102223A
(ko)
|
2014-11-07 |
2017-09-08 |
시그모이드 파마 리미티드 |
사이클로스포린을 포함하는 조성물
|
WO2016077629A1
(en)
|
2014-11-14 |
2016-05-19 |
Essentialis, Inc. |
Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome
|
US10398662B1
(en)
|
2015-02-18 |
2019-09-03 |
Jazz Pharma Ireland Limited |
GHB formulation and method for its manufacture
|
US20170042806A1
(en)
|
2015-04-29 |
2017-02-16 |
Dexcel Pharma Technologies Ltd. |
Orally disintegrating compositions
|
CA2989581A1
(en)
|
2015-06-17 |
2016-12-22 |
Biogen Ma Inc. |
Dimethyl fumarate particles and pharmaceutical compositions thereof
|
US10328087B2
(en)
|
2015-07-23 |
2019-06-25 |
Therapeuticsmd, Inc. |
Formulations for solubilizing hormones
|
US9675585B1
(en)
|
2016-03-24 |
2017-06-13 |
Ezra Pharma |
Extended release pharmaceutical formulations
|
US9687475B1
(en)
|
2016-03-24 |
2017-06-27 |
Ezra Pharma Llc |
Extended release pharmaceutical formulations with controlled impurity levels
|
US10286077B2
(en)
|
2016-04-01 |
2019-05-14 |
Therapeuticsmd, Inc. |
Steroid hormone compositions in medium chain oils
|
BR112018070199A2
(pt)
|
2016-04-01 |
2019-01-29 |
Therapeuticsmd Inc |
composição farmacêutica de hormônio esteroide
|
US10076494B2
(en)
|
2016-06-16 |
2018-09-18 |
Dexcel Pharma Technologies Ltd. |
Stable orally disintegrating pharmaceutical compositions
|
US11602512B1
(en)
|
2016-07-22 |
2023-03-14 |
Flamel Ireland Limited |
Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
|
US11602513B1
(en)
|
2016-07-22 |
2023-03-14 |
Flamel Ireland Limited |
Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
|
UY37341A
(es)
|
2016-07-22 |
2017-11-30 |
Flamel Ireland Ltd |
Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
|
US11504347B1
(en)
|
2016-07-22 |
2022-11-22 |
Flamel Ireland Limited |
Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
|
US20180263936A1
(en)
|
2017-03-17 |
2018-09-20 |
Jazz Pharmaceuticals Ireland Limited |
Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
|
CN106943356B
(zh)
*
|
2017-05-10 |
2019-11-08 |
武汉人福药业有限责任公司 |
一种泛昔洛韦缓释颗粒剂及其制备方法
|
EP3740189A1
(en)
|
2017-12-18 |
2020-11-25 |
Tris Pharma, Inc. |
Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
|
WO2019126214A1
(en)
|
2017-12-18 |
2019-06-27 |
Tris Pharma, Inc. |
Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release
|
CA3085941A1
(en)
|
2017-12-18 |
2019-06-27 |
Tris Pharma, Inc. |
Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
|
KR20210094513A
(ko)
|
2018-11-19 |
2021-07-29 |
재즈 파마슈티칼즈 아일랜드 리미티드 |
알코올-내성 약물 제형
|
CA3127871A1
(en)
|
2019-03-01 |
2020-09-10 |
Flamel Ireland Limited |
Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
|
US11633405B2
(en)
|
2020-02-07 |
2023-04-25 |
Therapeuticsmd, Inc. |
Steroid hormone pharmaceutical formulations
|
US11779557B1
(en)
|
2022-02-07 |
2023-10-10 |
Flamel Ireland Limited |
Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
|
US11583510B1
(en)
|
2022-02-07 |
2023-02-21 |
Flamel Ireland Limited |
Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
|